XBiotech Inc
Suletud
2.43 -2.02
Ülevaade
Aktsiahinna muutus
24h
Min
2.41
Max
2.49
Sissetulek | -21M -27M |
|---|---|
Aktsiakasum | -0.882 |
Töötajad | 85 |
EBITDA | -24M -29M |
Järgmine tulemuste avaldamine | 19. mai 2026 |
|---|
Turukapital | 3.7M 75M |
|---|---|
Eelmine avamishind | 4.45 |
Eelmine sulgemishind | 2.43 |
Tehniline skoor
By Trading Central
Kindlus
Bullish Evidence
XBiotech Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
XBiotech Inc Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.